Double-Blind, Dose Escalating, Randomized, Vehicle-Controlled Proof of Concept Clinical Trial of Patidegib Gel 2%, 4%, and Vehicle Applied Once or Twice Daily to Decrease the GLI1 Biomarker in Sporadic Nodular Basal Cell Carcinomas

Trial Profile

Double-Blind, Dose Escalating, Randomized, Vehicle-Controlled Proof of Concept Clinical Trial of Patidegib Gel 2%, 4%, and Vehicle Applied Once or Twice Daily to Decrease the GLI1 Biomarker in Sporadic Nodular Basal Cell Carcinomas

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 16 Sep 2017

At a glance

  • Drugs Patidegib (Primary)
  • Indications Basal cell cancer
  • Focus Adverse reactions; Proof of concept; Therapeutic Use
  • Acronyms BCC
  • Sponsors PellePharm
  • Most Recent Events

    • 31 Jul 2017 According to a PellePharm media release, Topline data from this trial is expected to be reported in Q4 2017.
    • 24 Jul 2017 Planned End Date changed from 1 Sep 2017 to 1 Oct 2017.
    • 24 Jul 2017 Planned primary completion date changed from 1 Sep 2017 to 1 Oct 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top